Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19.
Ann Neurol
; 89(3): 598-603, 2021 03.
Article
in English
| MEDLINE | ID: covidwho-1086259
ABSTRACT
We diagnosed 11 Guillain-Barré syndrome (GBS) cases among 71,904 COVID patients attended at 61 Spanish emergency departments (EDs) during the 2-month pandemic peak. The relative frequency of GBS among ED patients was higher in COVID (0.15) than non-COVID (0.02) patients (odds ratio [OR] = 6.30, 95% confidence interval [CI] = 3.18-12.5), as was the standardized incidence (9.44 and 0.69 cases/100,000 inhabitant-years, respectively, OR = 13.5, 95% CI = 9.87-18.4). Regarding clinical characteristics, olfactory-gustatory disorders were more frequent in COVID-GBS than non-COVID-GBS (OR = 27.59, 95% CI = 1.296-587) and COVID-non-GBS (OR = 7.875, 95% CI = 1.587-39.09) patients. Although COVID-GBS patients were more frequently admitted to intensive care, mortality was not increased versus control groups. Our results suggest SARS-CoV-2 could be another viral infection causing GBS. ANN NEUROL 2021;89598-603.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Taste Disorders
/
Hospital Mortality
/
Guillain-Barre Syndrome
/
COVID-19
/
Intensive Care Units
/
Length of Stay
/
Olfaction Disorders
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
English
Journal:
Ann Neurol
Year:
2021
Document Type:
Article
Affiliation country:
Ana.25987
Similar
MEDLINE
...
LILACS
LIS